

Jonathan G Howlett

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2651178/jonathan-g-howlett-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

10,630
citations

47
h-index

102
g-index

159
ext. papers

13,873
ext. citations

6.1
avg, IF

5.66
L-index

#	Paper	IF	Citations
136	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
135	Effect of nesiritide in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , 2011 , 365, 32-43	59.2	930
134	Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 1451-9	27.4	493
133	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 506-525	3.8	348
132	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1342-1433	3.8	330
131	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 23-45	3.8	323
130	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 569-88	3.8	314
129	N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. <i>Circulation</i> , 2007 , 115, 3103-10	16.7	251
128	HFSA 2006 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2006 , 12, e1-2	3.3	241
127	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 549-68	3.8	222
126	HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. <i>Heart Rhythm</i> , 2008 , 5, 907-25	6.7	214
125	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 557-576	3.8	205
124	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 485-501	3.8	198
123	Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 465-74	27.4	179
122	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) and in collaboration with the American College of Cardiology (ACC), the	3.9	177
121	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116 e Heart Fail. <i>Europace</i> , 2008 , 10, 707-25	59.2	164
120	The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 168-81	3.8	157

119	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	27.4	155
118	The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 528-42	3.8	147
117	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	12.3	145
116	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 596-624	3.8	139
115	The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 270-87	3.8	133
114	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 249-58	3.8	131
113	The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 319-38	3.8	123
112	The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>Journal of the American College of Cardiology</i> , 2006 , 47, 726-33	15.1	120
111	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 21-45	3.8	110
110	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 185-202	3.8	105
109	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 287-98	3.8	97
108	Relation of depression to severity of illness in heart failure (from Heart Failure And a Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]). <i>American Journal of Cardiology</i> , 2009 , 103, 1285-9	3	93
107	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	9.5	80
106	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 21-40	3.8	78
105	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 3-16	3.8	77
104	The relationship of quality of life, depression, and caregiver burden in outpatients with congestive heart failure. <i>Congestive Heart Failure</i> , 2005 , 11, 303-10		76
103	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 465-75	3.8	69
102	Treating the right patient at the right time: access to heart failure care. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 749-54	3.8	69

101	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 296-310	3.8	65
100	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 85-105	3.8	64
99	Prospective evaluation of nocturnal oximetry for detection of sleep-related breathing disturbances in patients with chronic heart failure. <i>Chest</i> , 2005 , 127, 1507-14	5.3	62
98	Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 553-61	15.1	57
97	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 921-929	12.3	53
96	Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. <i>Hypertension</i> , 2008 , 51, 48-54	8.5	53
95	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	16.7	52
94	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016 , 4, E365-E370	2.5	52
93	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 159-169 ³⁸	3.8	50
92	A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 769-72	3.8	50
91	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 531-546	3.8	48
90	Exercise capacity and cardiovascular adaptations to aerobic training early after stroke. <i>Topics in Stroke Rehabilitation</i> , 2005 , 12, 31-44	2.6	47
89	Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving beta-blocker therapy: data from the HF-ACTION trial. <i>European Heart Journal</i> , 2013 , 34, 2271-80	9.5	44
88	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418 ⁴⁰	9.5	40
87	Prognostic Value of Right Ventricular Strain Using Speckle-Tracking Echocardiography in Pulmonary Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1069-1078 ³⁸	3.8	37
86	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 249-63	3.8	36
85	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 700-710 ⁹⁵	9.5	35
84	Palliative care in heart failure: addressing the largest care gap. <i>Current Opinion in Cardiology</i> , 2011 , 26, 144-8	2.1	34

83	Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. <i>Annals of Internal Medicine</i> , 2014 , 161, 392-9	8	33
82	Determinants of early readmission after hospitalization for heart failure. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 612-8	3.8	31
81	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 932-942	12.3	29
80	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019 , 40, 2110-2117	9.5	29
79	Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. <i>Journal of Heart and Lung Transplantation</i> , 2005 , 24, 798-809	5.8	29
78	Implantable cardioverter-defibrillator implantation as a bridge to cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007 , 26, 1336-9	5.8	28
77	Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2019 , 25, 147-153	3.3	27
76	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 322-334	3.8	27
75	Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009 , 157, 219-28	4.9	27
74	Heart failure clinics are associated with clinical benefit in both tertiary and community care settings: data from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) registry. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e306-11	3.8	27
73	Current state of cardiac amyloidosis. <i>Current Opinion in Cardiology</i> , 2013 , 28, 242-8	2.1	25
72	The Canadian Heart Health Strategy and Action Plan: Cardiac rehabilitation as an exemplar of chronic disease management. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 37-41	3.8	25
71	End-of-life planning in heart failure: it should be the end of the beginning. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 135-41	3.8	25
70	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. <i>ESC Heart Failure</i> , 2017 , 4, 301-311	3.7	24
69	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171	12.3	24
68	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 1771-8	3	23
67	Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008 , 27, 197-202	5.8	23
66	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. <i>BMC Cardiovascular Disorders</i> , 2014 , 14, 91	2.3	22

65	The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 254-61	3.8	22
64	External Validation of the HF-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2019 , 139, 2377-2379	16.7	21
63	Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, S29-37	3.8	21
62	Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 6, 534-42	5.8	21
61	Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. <i>Transplant International</i> , 2010 , 23, 31-7	3	21
60	Posterior annular plication: tricuspid valve repair in Ebstein's anomaly. <i>Annals of Thoracic Surgery</i> , 2004 , 77, 2167-71	2.7	21
59	Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 792-9	3.8	20
58	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	16.7	20
57	Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013 , 1, 523-30	7.9	19
56	Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. <i>Transplantation</i> , 2008 , 85, 992-9	1.8	17
55	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 878-887	7.9	15
54	The effect of spironolactone use on heart failure mortality: a population-based study. <i>Journal of Cardiac Failure</i> , 2007 , 13, 165-9	3.3	15
53	Identifying opportunities to address the congestive heart failure burden: the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. <i>Canadian Journal of Cardiology</i> , 2003 , 19, 439-44	3.8	15
52	Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	14
51	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
50	Factors Associated With 7-Day Rehospitalization After Heart Failure Admission. <i>Journal of Cardiovascular Nursing</i> , 2017 , 32, 339-347	2.1	12
49	Outcomes in patients undergoing cardiac retransplantation: A propensity matched cohort analysis of the UNOS Registry. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 1067-1074	5.8	12
48	Canadian Consensus on cardiac transplantation in pediatric and adult congenital heart disease patients 2004: executive summary. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 1145-7	3.8	11

47	Specialist heart failure clinics must evolve to stay relevant. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 276-80	3.8	10
46	A qualitative study of the current state of heart failure community care in Canada: what can we learn for the future?. <i>BMC Health Services Research</i> , 2015 , 15, 290	2.9	10
45	Cardiovascular Fitness and Adaptations to Aerobic Training after Stroke. <i>Physiotherapy Canada Physiotherapie Canada</i> , 2006 , 58, 103-113	0.8	10
44	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1282-92	3.8	9
43	Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2015 , 30, 168-172	2.1	9
42	Acute heart failure: lessons learned so far. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 284-95	3.8	9
41	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	9
40	Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. <i>ESC Heart Failure</i> , 2018 , 5, 172-183	3.7	8
39	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020 , 43, 2878-2881	14.6	8
38	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. <i>ESC Heart Failure</i> , 2018 , 5, 19-26	3.7	7
37	Initiation of ivabradine in cardiogenic shock. <i>ESC Heart Failure</i> , 2019 , 6, 1088-1091	3.7	7
36	Metabolic syndrome and its components in individuals undergoing rehabilitation after stroke. <i>Journal of Neurologic Physical Therapy</i> , 2009 , 33, 189-94	4.1	7
35	Evidence of increasing public participation in advance care planning: a comparison of polls in Alberta between 2007 and 2013. <i>BMJ Supportive and Palliative Care</i> , 2019 , 9, 189-196	2.2	7
34	Physician specialty and quality of care for CHF: different patients or different patterns of practice?. <i>Canadian Journal of Cardiology</i> , 2003 , 19, 371-7	3.8	7
33	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 632-643	3.8	6
32	Relationships among achieved heart rate, Eblocker dose and long-term outcomes in patients with heart failure with atrial fibrillation. <i>Open Heart</i> , 2016 , 3, e000520	3	6
31	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021 , 23, 1662-1672	12.3	6
30	Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 432-440	3.8	5

29	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
28	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020 , 9, e017278	6	5
27	Does heart rate really matter to patients with heart failure?. <i>Current Opinion in Cardiology</i> , 2017 , 32, 209-216	2.1	4
26	Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction. <i>BMC Cardiovascular Disorders</i> , 2015 , 15, 46	2.3	4
25	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020 , 2, 151-160 ²		4
24	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 2725-2733	3.7	4
23	Surgical Treatment of Ischemic Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2011 , 17, 971-972	3.3	4
22	Canadian Cardiovascular Society Consensus Conference 2002: Management of heart disease in the elderly patient. <i>Canadian Journal of Cardiology</i> , 2004 , 20 Suppl A, 7A-16A	3.8	4
21	Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Nephilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction. <i>CJC Open</i> , 2020 , 2, 447-453	2	3
20	A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1089.e1-1089.e3	3.8	3
19	Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 199-208	2.5	3
18	Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2018 , 5, 2054358118804838	2.3	3
17	Randomized, Placebo-Controlled Trial of the Angiotensin Receptor Antagonist Losartan for Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2021 , 90, 473-481	7.9	3
16	Thrombus formation on an atrial septal defect closure device. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 68-70	3.8	3
15	Computerized Electronic Order Set: Use and Outcomes for Heart Failure Following Hospitalization. <i>CJC Open</i> , 2020 , 2, 497-505	2	2
14	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
13	Cardiac remodelling predicts outcome in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
12	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.. <i>Lancet, The</i> , 2022 , 399, 1391-1400	40	2

11	Dancing Cats, Heart Failure, and Circulating Troponin. <i>Journal of Cardiac Failure</i> , 2019 , 25, 238-239	3.3	1
10	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. <i>Circulation: Heart Failure</i> , 2020 , 13, e006952	7.6	1
9	Integration of monitoring technology for heart failure. <i>Current Opinion in Cardiology</i> , 2012 , 27, 130-6	2.1	1
8	I have heart failure - what happens now, Doc?. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 695-6	3.8	1
7	Response to Letter Regarding Article, N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study <i>Circulation</i> , 2008 , 117,	16.7	1
6	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , 2022 , 10, 52-64	7.9	1
5	Heart failure guidelines fail. <i>Cmaj</i> , 2015 , 187, 912	3.5	
4	Traitement du diabète chez les personnes atteintes d'insuffisance cardiaque. <i>Canadian Journal of Diabetes</i> , 2013 , 37, S501-S503	2.1	
3	Pancytopenia with hypercellular bone marrow secondary to cytomegalovirus after cardiac transplant. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 749-50	5.8	
2	Acutely decompensated congestive heart failure: new therapies for an old problem. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 925-36	2.5	
1	Should we inhibit angiotensin-converting enzymes in acute heart failure?. <i>Heart Failure Monitor</i> , 2007 , 5, 70-6		